ATNM Actinium Pharmaceuticals, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1388320 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY130.6%
TTM EPS YoY130.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE55.2%
ROA23.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.20x
Accruals ratio76.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $90,000 | — | $81,000 | $1.03M | $1.14M |
| Cost of revenue | — | — | — | — | $900,000 |
| Gross profit | — | — | — | — | $244,000 |
| R&D expense | $21.12M | $30.05M | $38.67M | $23.14M | $18.03M |
| SG&A expense | $15.21M | $12.08M | $13.33M | $12.00M | $8.08M |
| Operating income | -$36.25M | -$42.12M | -$51.92M | -$34.10M | -$24.96M |
| Pretax income | -$33.29M | -$38.24M | — | — | — |
| Net income | -$33.89M | -$38.24M | -$48.82M | -$33.02M | -$24.77M |
| EBITDA | -$36.07M | -$41.92M | -$51.71M | -$33.41M | -$24.44M |
| EPS (basic) | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 |
| EPS (diluted) | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 |
| Weighted avg. shares (diluted) | 31.20M | 30.07M | 26.60M | 24.14M | 20.57M |
| Banking | |||||
| Net interest income | — | — | $3.10M | $1.09M | $190,000 |
| Balance sheet | |||||
| Cash & equivalents | $48.00M | $73.23M | $76.99M | $109.61M | $78.22M |
| Current assets | $49.38M | $74.51M | $78.26M | $110.94M | $79.75M |
| PP&E, net | $295,000 | $364,000 | $550,000 | $604,000 | $340,000 |
| Total assets | $51.77M | $76.90M | $81.44M | $114.19M | $80.39M |
| Current liabilities | $7.97M | $8.15M | $8.49M | $10.63M | $6.84M |
| Total liabilities | $43.94M | $44.14M | $45.07M | $47.71M | $6.84M |
| Shareholders' equity | $7.83M | $32.76M | $36.38M | $66.48M | $73.55M |
| Shares outstanding | 31.20M | 31.20M | 27.63M | 25.67M | 22.14M |
| Cash flow statement | |||||
| Operating cash flow | -$24.58M | -$33.07M | -$47.34M | $8.64M | -$20.87M |
| Capital expenditure | $104,000 | $11,000 | $153,000 | $366,000 | $133,000 |
| Free cash flow | -$24.68M | -$33.08M | -$47.49M | $8.28M | -$21.00M |
| Investing cash flow | -$104,000 | -$11,000 | -$153,000 | -$366,000 | -$133,000 |
| Financing cash flow | -$217,000 | $29.32M | $14.87M | $23.11M | $35.22M |
| Depreciation & amortization | $173,000 | $197,000 | $207,000 | $699,000 | $524,000 |
| Stock-based compensation | $9.19M | $5.29M | $3.84M | $2.79M | $1.69M |
Free plan shows the latest 5 periods; Pro shows all 25 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.